

Remarks

Amendments to the Claims

Claims 1-52 were pending in this application. Claims 29-33, 40-43, and 52 are cancelled herein as drawn to non-elected Groups. Applicants expressly reserve the right to pursue protection of any or all of the cancelled claims in a subsequent application.

In addition, new claims 53-83 are added. The language of the new claims finds support throughout the specification and in the claims as originally filed. In particular, support for claim 53 can be found in claim 37; support for claim 54 can be found on page 37 (describing application of microspots to arrays). Support for analysis of more than one protein content of more than one cell (as recited in new claims 55-83) can be found in the original claims and throughout the specification, including the description in Example 6, beginning at page 36, line 11 (describing Multiplexed Tissue Arrays, including production of samples and arrangement of multiple samples for analysis).

No new matter is introduced by these amendments. After entry of this amendment, **claims 1-28, 34-39, and 44-83 are pending in the application.**

Request for Acknowledgement of Priority Applications

Applicants note that the Office has not yet acknowledged (in writing or on the PAIR system) the domestic priority claim made under 35 USC §119(e) in this application. This application is the National Stage of International Application No. PCT/US00/04023, filed February 16, 2000, and claims the benefit of U.S. Provisional Application No. 60/120,288, filed February 16, 1999. This information was provided to the Office on the Declaration that was filed with the application on August 16, 2001, and was entered into the text of the application by Preliminary Amendment filed on the same date. Applicants request that the Examiner ensure that this information is correctly entered into the application, and acknowledge the priority claim in the next action.

Response to Restriction Requirement

As a preliminary matter, Applicants request that the Examiner clarify the claims that are assigned to Group III. Though the Restriction Requirement indicates claims 40-52, Applicants believe that this should be 40-42 (so that each claim is assigned to only one Group) and request that the Examiner confirm this.

In response to the Restriction Requirement, Applicants elect Examiner's Group I (drawn to method of analyzing protein content, claims 1-28, 34-39, and 44-51) without traverse. Applicants have added new claims 53-83, which are also directed to aspects of Examiner's Group I and therefore can be examined in the current case.

Finally, Applicants have amended the Title, to better reflect the subject matter they have elected to pursue in the current application.

Conclusion

Examiner Minnifield is invited to telephone the undersigned if any questions remain concerning the requirement for restriction, or the amendments made herein. Otherwise, the present application is ready for substantive examination, and such action is requested.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446